Bill joined OUP in 2012. Along with the other Managing Partners, Bill is responsible for overseeing and approving all Partnership investments and all other Partnership and organizational activities. Bill is responsible for overseeing all life science investment activities of the Partnership, and along with Marc, is responsible for day to day execution of the Partnership. At the present time, Bill serves on the boards of OUP portfolio companies Hyalex Orthopedics, Neuros Medical, and MediSix Therapeutics. Bill previously served on the boards of OUP portfolio companies Millendo Therapeutics (NASDAQ: MLND) and Ribon Therapeutics. Bill has spent the last 20 years in venture capital. In 1999, he joined Three Arch Partners, a west coast venture capital firm with over $1 billion under management. Bill served as a General Partner at Three Arch Partners, where he focused on investing in life science companies including therapeutics, medical devices, and healthcare services. He left Three Arch Partners at the end of 2011 to join OUP. Prior to joining Three Arch, Bill served as a practicing Interventional Radiologist in the San Francisco Bay Area.
Bill earned his B.S. from Tufts University, summa cum laude, an M.D. from Harvard Medical School, and an M.B.A. from the Haas Business School, University of California, Berkeley. Bill is a holder of the Chartered Financial Analyst designation. Bill is a member of the Board of Trustees at The Haverford School in Haverford, PA.
Bill resides in Haverford, PA with his wife Leda and their two children.
Education
- BS, Tufts University
- MD, Harvard Medical School
- MBA, UC Berkeley
Investments
- Aerie Pharmaceuticals
- Aerovate Therapeutics
- AGTC
- Antiva Biosciences
- Aptinyx
- Arrakis Therapeutics
- ArsenalBio
- Artizan Biosciences
- Atsena Therapeutics
- Avid Radiopharmaceuticals
- Beam Therapeutics
- Biohaven Pharmaceuticals
- Blade Therapeutics
- Capella Bioscience
- Cardioxyl Pharmaceuticals
- Cell Design Labs
- Chroma Medicine
- Coho Therapeutics
- Cyteir Therapeutics
- DICE Therapeutics
- Dracen Pharmaceuticals
- eFFECTOR Therapeutics
- eGenesis
- E-Scape Bio
- Escient Pharmaceuticals
- Faraday Pharmaceuticals
- Fortis Therapeutics
- Graphite Bio
- Guardant Health
- Homology Medicines
- Hyalex Orthopaedics
- Iconic Therapeutics
- Immune Design
- Interius BioTherapeutics
- Kolltan Pharmaceuticals
- Kura Oncology
- Landos Biopharma
- MediSix Therapeutics
- MicroTransponder
- Millendo Therapeutics
- Modis Therapeutics
- Neuros
- Nocion Therapeutics
- Normunity
- Otonomy
- Palladio Biosciences
- Pionyr Immunotherapeutics
- PMV Pharmaceuticals
- Precision Biosciences
- Prime Medicine
- Q32 Bio
- Receptos
- ReCode Therapeutics
- Ribon Therapeutics
- Sana Biotechnology
- Satsuma Pharmaceuticals
- Selecta Biosciences
- Sera Prognostics
- Sonoma Biotherapeutics
- Spero Therapeutics
- Synthorx
- Redona Therapeutics
- Vanqua Bio
- Vor Biopharma